from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A P2Y12 inhibitor under investigation as an antiplatelet drug for intravenous application.


Sorry, no etymologies found.


  • Medicines Co. lost 4.12, or 37%, to 7.02, as the pharmaceutical company said it is discontinuing its Phase III "Champion" clinical trial of cangrelor in patients undergoing percutaneous coronary intervention.

    Liz Fizzes; Nixed Trial Makes Medicines Go Down

  • TMC is currently spending about $100m on R&D, 60% of which is dedicated to cangrelor and oritavancin, according to TMC's latest quarterly report.

  • Although the potential of cangrelor and oritavancin is clear, the key caveat here is 'potential,' given the big clinical and regulatory challenges both products still face.

  • Licensed from Astra in 2003, TMC had to ditch a pivotal 15,000 patient trial programme for cangrelor in 2009 as the drug failed to show any advantage over gold standard antiplatelet drug .

  • However, TMC continues to see potential in cangrelor, particularly as an agent which can be used in patients that have to stop taking Plavix ten days prior to cardiac surgery due to its short half-life.

  • As for the late stage pipeline, TMC is pushing on with the development of cangrelor, a platelet aggregation inhibitor in the same class as .

  • The company increased research and development spending to $26.5 million, from $20.6 million a year earlier, with the blood drug cangrelor, and the antibiotic oritavancin, in late-stage clinical trials.

  • Harrington et al. 1 and Bhatt et al. 2 (Dec. 10 issue) describe the results of studies of platelet inhibition with intravenous cangrelor in patients undergoing percutaneous coronary intervention (PCI).

    Medlogs - Recent stories

  • The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development.

    Marketwire - Breaking News Releases

  • Medicines Co. blood thinner still has hope: doctors trials warranted * Say lower mortality, stent clots justify further study * Caution that cangrelor failed earlier main study goals By Ransdell Pierson and - Articles related to Women and Coronary Artery Disease


Log in or sign up to get involved in the conversation. It's quick and easy.